Sugi Predict

Sugi Predict / Targets / FCGRT

FCGRT

IgG receptor FcRn large subunit p51 · P55899 · FCGRT on Sugi Atlas →

376 patent compounds predicted against FCGRT, 199 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL30290900 SCHEMBL30290900 0.74 14/20
SCHEMBL29506656 SCHEMBL29506656 0.71 14/20
SCHEMBL31060851 SCHEMBL31060851 0.64 12/20
SCHEMBL30143383 SCHEMBL30143383 0.52 11/20
SCHEMBL30197709 SCHEMBL30197709 0.59 8/20
SCHEMBL29931197 SCHEMBL29931197 0.57 8/20
SCHEMBL29371217 SCHEMBL29371217 0.56 8/20
SCHEMBL30514724 SCHEMBL30514724 0.54 8/20
SCHEMBL31323238 SCHEMBL31323238 0.53 8/20
SCHEMBL30313476 SCHEMBL30313476 0.55 7/20
SCHEMBL29453009 SCHEMBL29453009 0.55 5/20
SCHEMBL12305037 SCHEMBL12305037 0.81 4/20
SCHEMBL14366165 SCHEMBL14366165 0.80 4/20
SCHEMBL12253738 SCHEMBL12253738 0.66 4/20
SCHEMBL12766288 SCHEMBL12766288 0.66 4/20
SCHEMBL10132153 SCHEMBL10132153 0.64 4/20
SCHEMBL12253644 SCHEMBL12253644 0.62 4/20
SCHEMBL29647870 SCHEMBL29647870 0.59 4/20
SCHEMBL30614509 SCHEMBL30614509 0.56 4/20
SCHEMBL29625818 SCHEMBL29625818 0.55 4/20

Clinical trials — most relevant to FCGRT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) PHASE4COMPLETED
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency PHASE3RECRUITING
Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis PHASE2COMPLETED
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL) PHASE2COMPLETED
A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis PHASE2COMPLETED
Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy PHASE2COMPLETED
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus PHASE2COMPLETED
Rituximab in the Treatment of Graves' Disease PHASE1/PHASE2COMPLETED
Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment PHASE2UNKNOWN
Post IVIG Medication in Children With Immune Thrombocytopenia PHASE1UNKNOWN
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma PHASE1COMPLETED
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies PHASE1COMPLETED
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation nanUNKNOWN
Prognostic Value of CD64 Marker for Patients in Intensive Care Unit nanUNKNOWN
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis. nanRECRUITING
Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus nanCOMPLETED
Fetal-Hope Study: Home Monitoring of Fetal Heart Rate in SSA+ Pregnant Women nanUNKNOWN
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis nanCOMPLETED
Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus nanRECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children nanNOT_YET_RECRUITING
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy nanCOMPLETED
S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone nanCOMPLETED
Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact nanRECRUITING
Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study nanNOT_YET_RECRUITING
Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus nanUNKNOWN
Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer nanCOMPLETED
Genotyping FcɣRs Genes of HIV-1 Patients Progressor: Correlation With the Changing Profile of the Infection nanUNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FCGRT binder may also engage these)

ProteinNameSimilarity
Q8SPV9 — 1.000 Q8SPV9 →
P13599 — 1.000 P13599 →
Q61559 — 1.000 Q61559 →
P60018 — 0.993 P60018 →
Q2KN22 — 0.992 Q2KN22 →
Q9GL43 — 0.991 Q9GL43 →
Q9GKZ0 — 0.991 Q9GKZ0 →
Q30201 — 0.990 Q30201 →
P70387 — 0.989 P70387 →
P30383 — 0.989 P30383 →
P30686 — 0.988 P30686 →
P13747 — 0.988 P13747 →
P14427 — 0.988 P14427 →
HLA-C HLA class I histocompatibility antigen, C alpha chain 0.986 landscape →
O35799 — 0.986 O35799 →
Q9GL41 — 0.986 Q9GL41 →
P30387 — 0.986 P30387 →
Q9GL42 — 0.986 Q9GL42 →
P01901 — 0.985 P01901 →
P03991 — 0.985 P03991 →
P01902 — 0.984 P01902 →
HLA-A HLA class I histocompatibility antigen, A alpha chain 0.984 landscape →
P13752 — 0.983 P13752 →
P13749 — 0.983 P13749 →
Q3ZCH5 — 0.983 Q3ZCH5 →
P14432 — 0.983 P14432 →
P13748 — 0.983 P13748 →
P06140 — 0.983 P06140 →
P30385 — 0.983 P30385 →
P14426 — 0.983 P14426 →